ProCE Banner Activity

Clinical Considerations for RET Fusion–Positive NSCLC

Podcast Episodes

Listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, including testing for RET fusions, using new selective RET inhibitors in these patients, and the importance of interdisciplinary communication.

Released: September 17, 2020

Expiration: September 16, 2021

Share

Faculty

Dara L. Aisner

Dara L. Aisner, MD, PhD

Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Dara L. Aisner, MD, PhD

Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado

Dara L. Aisner, MD, PhD, has disclosed that she has received consulting fees from Blueprint Medicines and Genentech.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.